Cosmo Bio Company,Limited (TYO:3386)
Japan · Delayed Price · Currency is JPY 1,307.00
-39.00 (-2.90%)
At close: Feb 16, 2026
Cosmo Bio Company,Limited Revenue
In the year 2025, Cosmo Bio Company,Limited had annual revenue of 10.77B JPY with 7.26% growth. Cosmo Bio Company,Limited had revenue of 2.88B in the quarter ending December 31, 2025, with 9.63% growth.
Revenue
10.77B
Revenue Growth
+7.26%
P/S Ratio
0.69
Revenue / Employee
61.87M
Employees
174
Market Cap
7.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.77B | 729.00M | 7.26% |
| Dec 31, 2024 | 10.04B | 697.00M | 7.46% |
| Dec 31, 2023 | 9.34B | -213.00M | -2.23% |
| Dec 31, 2022 | 9.55B | 322.00M | 3.49% |
| Dec 31, 2021 | 9.23B | 1.14B | 14.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.46T |
| Otsuka Holdings | 2.42T |
| Chugai Pharmaceutical | 1.26T |
| HOYA Corporation | 915.21B |
| UCHIYAMA HOLDINGS | 29.44B |
| OncoTherapy Science | 784.00M |
| Chiome Bioscience | 727.99M |
| Solasia Pharma K.K. | 326.00M |